Bioequivalence Study of Two Inhalation Formulations Containing Budesonide 200 µg

NCT02593500 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Allergy

Interventions

DRUG: Budesonida Pulmictan® 200 µg
DRUG: Budesonide 200 µg

Sponsor

Reig Jofre Group